GCVRZ News and Press, Sanofi Contingent Value Right (Expiring 12/31/2020) From 12/14/23

2023-12-14 15:46:45 ET More on AstraZeneca, Sanofi, etc. AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Is Feeling The Weight Of The Market In 2023 R&D Day AbbVie, AstraZeneca targeted for improper use of drug patents I...

2023-11-24 12:35:42 ET More on BioNTech, GSK, etc. BioNTech Vs. Moderna: Navigating The mRNA Landscape Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips Moderna Nears Key Technical Level With Indications Of Reversal (Rating Upgrade) GSK makes ...

2023-11-19 12:00:00 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Perfectly Priced Healthcare Giant Novo Nordisk A/S (NVO) Novo Nordisk R&D Investor Event (Transcript) Eli Lilly: Favorable Developments Continue Regarding Anti-Obesity Drug Franchise ...

2023-11-09 14:02:39 ET More on UnitedHealth UnitedHealth Group: Excellent Healthcare Stock To Buy UnitedHealth Group: Be Prepared For The Next Buying Opportunity UnitedHealth Group: Market Leaders Never Come Cheap UnitedHealth PBM raises reimbursement tier fo...

2023-11-07 07:30:58 ET More on Sanofi Sanofi Spins Off, Investors Spin Out (Rating Downgrade) Sanofi (SNY) Q3 2023 Earnings Call Transcript Sanofi Q3 2023 Earnings Preview: Expect Positive Results, But No Share Price Spike Sanofi shares hit 52-week low amid d...

2023-11-03 08:40:40 ET More on Regeneron Regeneron Pharmaceuticals, Inc. (REGN) Q3 2023 Earnings Call Transcript Regeneron Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare ...

2023-10-31 12:24:58 ET Summary Amicus Therapeutics, Inc. is a commercial-stage biotech company focused on developing therapies for rare diseases. The company recently received FDA approval for its combination therapy Pombiliti + Opfolda for Pompe disease. Amicus Therapeutics i...

2023-10-27 01:41:02 ET More on Sanofi, Sanofi, etc. Sanofi: 3 Reasons For A Buy Sanofi: A 'Buy' Recommendation For Undervalued Growth Potential FDA rejects Regeneron-Sanofi's Dupixent application for chronic hives, wants more data GoodRx to offer Sanofiȁ...

2023-10-26 10:53:55 ET More on BioNTech, GSK, etc. Pfizer: Ignore The Noise And Buy This Deep Value Seagen's Acquisition: EU Approval And Potential Upside Pfizer: Huge Upside Potential And 5%+ Yield Pfizer, BioNTech post early-stage data for COVID-flu combo s...

2023-10-19 09:58:30 ET More on Sanofi, GoodRx, etc. GoodRx Faces Challenges In Subscription Plans, But Its Valuation Already Prices This In GoodRx Stock: Earnings Momentum Keeps It Interesting Sanofi: 3 Reasons For A Buy Sanofi presents encouraging data on at...